inhibitor of DNA binding 1Genealiases: ID · bHLHb24
Q-omics provides the consensus-scored ID1 profile across patient tissues and cancer cell-line models. ID1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ID1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ID1 RNA expression shows 14,858 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where ID1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ID1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ID1 survival associations across molecular data types. ID1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ID1 RNA expression–survival associations across cancer types. High ID1 expression shows unfavorable associations in LUAD, UVM, CESC and LAML, but favorable associations in BLCA and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ID1 RNA expression.
This table summarizes ID1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ID1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ID1 shows lower tumor expression in KIRC, THCA, KICH, LIHC, LUAD and BRCA. The KIRC box plot shows higher ID1 RNA expression in normal versus tumor tissue (log2 FC = −1.317, t-test p < 0.001).
This table shows molecular features associated with ID1 in patient tissues and cancer cell lines. In patient samples, ID1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ID1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
